Syndax in-licenses portfolio of blood cancer candidates

19 October 2017
2019_biotech_test_vial_discovery_big

US oncology-focussed biotech firm Syndax Pharmaceuticals (Nasdaq: SNDX) has entered into an exclusive worldwide license agreement with Vitae Pharmaceuticals, a subsidiary of Ireland-incorporated Allergan (NYSE: AGN), for a portfolio of preclinical, orally-available small molecule inhibitors of the interaction of Menin with the mixed lineage leukemia (MLL) protein.

These compounds have potential application in the treatment of a genetically-defined subset of acute leukemias with chromosomal rearrangements in the MLL gene (MLL-r). Syndax expects to initiate clinical studies in 2019. Syndax itself is developing entinostat (also in combination with Merck KGaA and Pfizer’s avelumab, as well as with Merck & Co’s Keytruda) and SNDX-6352 in multiple cancer indications.

Financial terms of the deal

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology